John LambertAnavex Pre-Clinical Results for Parkinson’sThis past week, Anavex Life Sciences (AVXL) reported the summary results of the pre-clinical trials of Anavex 2–73 for Parkinson’s, and the…2 min read·Sep 24, 2016----
John LambertBackgrounder on Epilepsy and Anavex Life SciencesAnavex Life Science’s leading drug candidate, Anavex 2–73, is now at the design stage for a pivotal phase 2/3 trial targeting Alzheimer’s…7 min read·Nov 20, 2015--1--1
John LambertThe Anavex Story for Honest InvestorsThis article is a rebuttal to one published yesterday purporting to tell the Anavex story. It doesn’t. It merely attacks Anavex with…14 min read·Nov 10, 2015--8--8